Actinium Pharma

ATNM

----

Current ValuationThe current P/E ratio is 4.23, above the reasonable range, cheaper than 0.13% of the time in the past 3 years, and the industry ranks 19/606, the industry Median -1.87.

4.23xP/E

Stock price$1.52Earnings per share$0.36

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.55x	72.02%	$23.45B
GRFSUSGRIFOLS SA	9.92x	45.10%	$5.20B
ACADUSAcadia Pharma	8.93x	73.21%	$3.40B
NRIXUSNurix Therapeutics	9.39x	191.12%	$2.77B
PURRUSHyperliquid Strategies	9.54x	67.60%	$2.44B
ADMAUSAdma Biologics	14.16x	35.42%	$2.39B
AUPHUSAurinia Pharma	7.14x	54.20%	$2.24B
LKFTUSLakefront Biotherapeutics	2.93x	86.45%	$2.03B
ANABUSAnaptysbio	5.56x	1,003.56%	$1.46B
VORUSVor BioPharma	1.72x	89.71%	$1.08B
BVNRYUSBavarian Nordic A/S	11.65x	--	$2.79B
RIGLUSRigel Pharma	2.79x	83.91%	$899.06M
MGTXUSMeiraGTx	11.20x	122.03%	$884.56M
ABUSUSArbutus Pharma	5.40x	535.59%	$827.15M
IRWDUSIronwood Pharma	4.40x	715.55%	$571.73M
AGENUSAgenus	3.10x	--	$284.98M
QTTBUSQ32 Bio	7.62x	162.04%	$257.51M
CUVLUSClinuvel Pharmaceuticals	10.85x	--	$249.11M
PLXUSProtalix Biotherap	10.84x	400.00%	$205.46M
CGENUSCompugen	5.22x	173.68%	$183.76M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.